(Total Views: 312)
Posted On: 03/16/2020 9:39:59 PM
Post# of 72441
Brilacidin
Innovation Pharmaceuticals Inc.
Phase II
Exploring its lead defensin mimetic candidate, brilacidin, as a treatment for the COVID-19; potential treatment also for otitis media or externa, skin diseases, Middle East respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus
Innovation Pharmaceuticals Inc.
Phase II
Exploring its lead defensin mimetic candidate, brilacidin, as a treatment for the COVID-19; potential treatment also for otitis media or externa, skin diseases, Middle East respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus
(3)
(0)Scroll down for more posts ▼
